Long-term outcomes for primary @entity631 : New Zealand XXXX study.

@entity1 @entity644 @entity8 @entity101 @entity628 @entity740 @entity631 @entity204 @entity454
AIMS: Due to the paucity of studies focusing on primary @entity631 , the second commonest cause of @entity454 in most of the developed world, we sought to review outcomes of these renal pathologies. METHODS: We reviewed outcomes of primary @entity631 in @entity1 enrolled in the New Zealand @entity631 Study between 1972 and 1983 focusing on renal outcomes and mortality. RESULTS: There were 765 @entity1 with a median follow-up of 30 years (range 0  1- 42years). They were predominantly New Zealand European, male and @entity101 . Poor renal outcomes and increased mortality were associated with @entity101 , @entity644 greater than 1g/day, reduced estimated glomerular filtration rate and older age at diagnosis. Ethnicity was not significantly associated with progression to @entity454 although indigenous NZ Maori @entity1 were at significantly increased risk of @entity204 . @entity1 diagnosed with rapidly progressive @entity631 were 5 times more likely than those with minimal change @entity8 to reach @entity454 . The cumulative incidence of @entity454 was approximately 20% for those with immunoglobulin-A @entity8 , and 30% @entity8 @entity1 . @entity1 with rapidly progressive @entity631 and @entity8 were at increased risk of @entity204 , although the latter were not at increased risk of @entity454 if they survived. The era of diagnosis did not have much effect on outcomes except for @entity1 diagnosed with @entity628 or immunoglobulin A @entity8 but this could be type II error. CONCLUSION: We report one of the longest follow-up studies on biopsy-proven @entity631 . Age, @entity101 , and severity of @entity740 at diagnosis were strong predictors of the development of @entity454 and @entity204 . The specific renal pathology had a profound impact upon prognosis and therefore should continue to drive efforts to find targeted therapeutic options for these @entity631 .
